People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Healthtech, Hospitals and Physicians, Other Health Care, Other, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Suneva Medical, Inc. | — | Healthtech | Series B | $140.2M | $24.9M | 2019 |
| U S HealthVest, LLC | — | Hospitals and Physicians | Series C | $125.3M | $212.6M | 2013 |
| Nomad Health, Inc. | — | Healthtech | Series B | $106.9M | $153.0M | 2025 |
| Respicardia, Inc. | — | Other Health Care | Series B | $92.4M | $443.1M | 2010 |
| BridgePoint Medical, Inc. | — | Other Health Care | Series A | $16.2M | $183.6M | 2009 |
| Ella Health, Inc. | — | Other Health Care | Series A | $14.0M | $30.3M | 2014 |
| Ajax Health III LLC | — | Healthtech | Series A | $10.1M | $228.5M | 2019 |
| Lola Development, LLC | — | Hospitals and Physicians | Series A | $6.7M | $125.1M | 2017 |
| Archus Orthopedics Inc | — | Other | Seed | $2.3M | $42.3M | 2009 |
| Novaerus Group Ltd | — | Other Technology | Seed | $1.8M | $59.6M | 2016 |
Brian Chee at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Brian Chee on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Garheng Kong | 2 | 16 |
| Richard Kresch | 2 | 3 |
| Brian G. Chee | 2 | 2 |
| Brian M. Chee | 2 | 2 |
| James Cha | 2 | 2 |
| Andrew Firlik | 1 | 14 |
| Peter Barton Hutt | 1 | 14 |
| Andrew Adams | 1 | 13 |
| John Nehra | 1 | 11 |
| Jonathan Lim | 1 | 9 |
| Jon Lim | 1 | 9 |
| Douglas Koo | 1 | 7 |
| Michael Berman | 1 | 7 |
| Scott Ward | 1 | 7 |
| Thomas Mawhinney | 1 | 5 |
| Jay K. Hachigian | 1 | 5 |
| Gilbert H. Kliman | 1 | 5 |
| B. KRISTINE JOHNSON | 1 | 5 |
| ROGER GUIDI | 1 | 5 |
| Dennis Condon | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.